Form 4: Kura Oncology COO Kathleen Ford Reports Stock Option Grant
SEC Filing
Kathleen Ford, Chief Operating Officer of Kura Oncology, reports the acquisition of stock options.
Summary
- Kathleen Ford, the Chief Operating Officer of Kura Oncology, filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on January 2, 2025.
- Ford acquired options to purchase 185,000 shares of Kura Oncology common stock at an exercise price of $8.68.
- The options vest in 48 equal monthly installments starting on the grant date and expire on January 1, 2035.
- Following the transaction, Ford directly owns options for 185,000 shares.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of stock options to the COO aligns her interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.
Stakeholder Impact
- The stock option grant could potentially incentivize the COO to improve company performance, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of earliest transaction (stock option grant) |
| 01/06/2025 | Date of Form 4 filing |
| 01/01/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.